Five of our most advanced and high-potential clinical and preclinical assets are being progressed to their next inflection points.

  • Target ID
  • Chemistry and Lead Optimisation
  • Preclinical
  • Phase I
  • Phase II
BEN-8744 Ulcerative Colitis
BEN-28010 Glioblastoma Multiforme
BEN-34712 ALS
Parkinson's disease
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Oncology, neurology, immunology

Regular re-evaluation of 10+ paused programmes and potential new pipeline entries